Pentwater Capital Management LP Cerevel Therapeutics Holdings, Inc. Transaction History

Pentwater Capital Management LP

  • $8.71 Billion
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024
SELL
$38.96 - $42.75 $13.3 Million - $14.6 Million
-341,281 Reduced 15.37%
1,878,719 $76.8 Million
Q1 2024

May 15, 2024
BUY
$40.88 - $43.27 $45.8 Million - $48.5 Million
1,120,000 Added 101.82%
2,220,000 $93.8 Million
Q4 2023

Feb 14, 2024
BUY
$20.27 - $42.44 $22.3 Million - $46.7 Million
1,100,000 New
1,100,000 $46.6 Million

Others Institutions Holding CERE

# of Institutions
7
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Pentwater Capital Management LP Portfolio

Follow Pentwater Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pentwater Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Pentwater Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email